Background: The comparative safety and effectiveness of treatments to prevent thromboembolic complications in atrial fibrillation (AF) remain uncertain. Purpose: To compare the effectiveness of medical and procedural therapies in preventing thromboembolic events and bleeding complications in adults with nonvalvular AF. Data Sources: English-language studies in several databases from 1 January 2000 to 14 February 2018. Study Selection: Two reviewers independently screened citations to identify comparative studies of treatments to prevent stroke in adults with nonvalvular AF who reported thromboembolic or bleeding complications. Data Extraction: Two reviewers independently abstracted data, assessed study quality and applicability, and rated strength of evidence. Data Synthesis: Data from 220 articles were included. Dabigatran and apixaban were superior and rivaroxaban and edoxaban were similar to warfarin in preventing stroke or systemic embolism. Apixaban and edoxaban were superior and rivaroxaban and dabigatran were similar to warfarin in reducing the risk for major bleeding. Treatment effects with dabigatran were similar in patients with renal dysfunction (interaction P > 0.05), and patients younger than 75 years had lower bleeding rates with dabigatran (interaction P < 0.001). The benefit of treatment with apixaban was consistent in many subgroups, including those with renal impairment, diabetes, and prior stroke (interaction P > 0.05 for all). The greatest bleeding risk reduction was observed in patients with a glomerular filtration rate less than 50 mL/min/1.73 m2 (P = 0.003). Similar treatment effects were observed for rivaroxaban and edoxaban in patients with prior stroke, diabetes, or heart failure (interaction P > 0.05 for all). Limitation: Heterogeneous study populations, interventions, and outcomes. Conclusion: The available direct-acting oral anticoagulants (DOACs) are at least as effective and safe as warfarin for patients with nonvalvular AF. The DOACs had similar benefits across several patient subgroups and seemed safe and efficacious for a wide range of patients with nonvalvular AF. Primary Funding Source: Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42017069999).
Background: The comparative safety and effectiveness of treatments to prevent thromboembolic complications in atrial fibrillation (AF) remain uncertain. Purpose: To compare the effectiveness of medical and procedural therapies in preventing thromboembolic events and bleeding complications in adults with nonvalvular AF. Data Sources: English-language studies in several databases from 1 January 2000 to 14 February 2018. Study Selection: Two reviewers independently screened citations to identify comparative studies of treatments to prevent stroke in adults with nonvalvular AF who reported thromboembolic or bleeding complications. Data Extraction: Two reviewers independently abstracted data, assessed study quality and applicability, and rated strength of evidence. Data Synthesis: Data from 220 articles were included. Dabigatran and apixaban were superior and rivaroxaban and edoxaban were similar to warfarin in preventing stroke or systemic embolism. Apixaban and edoxaban were superior and rivaroxaban and dabigatran were similar to warfarin in reducing the risk for major bleeding. Treatment effects with dabigatran were similar in patients with renal dysfunction (interaction P > 0.05), and patients younger than 75 years had lower bleeding rates with dabigatran (interaction P < 0.001). The benefit of treatment with apixaban was consistent in many subgroups, including those with renal impairment, diabetes, and prior stroke (interaction P > 0.05 for all). The greatest bleeding risk reduction was observed in patients with a glomerular filtration rate less than 50 mL/min/1.73 m2 (P = 0.003). Similar treatment effects were observed for rivaroxaban and edoxaban in patients with prior stroke, diabetes, or heart failure (interaction P > 0.05 for all). Limitation: Heterogeneous study populations, interventions, and outcomes. Conclusion: The available direct-acting oral anticoagulants (DOACs) are at least as effective and safe as warfarin for patients with nonvalvular AF. The DOACs had similar benefits across several patient subgroups and seemed safe and efficacious for a wide range of patients with nonvalvular AF. Primary Funding Source: Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42017069999).
Authors: Meena P Rao; Dragos Vinereanu; Daniel M Wojdyla; John H Alexander; Dan Atar; Elaine M Hylek; Michael Hanna; Lars Wallentin; Renato D Lopes; Bernard J Gersh; Christopher B Granger Journal: Am J Med Date: 2017-11-06 Impact factor: 4.965
Authors: Dragos Vinereanu; Susanna R Stevens; John H Alexander; Sana M Al-Khatib; Alvaro Avezum; Marıa Cecilia Bahit; Christopher B Granger; Renato D Lopes; Sigrun Halvorsen; Michael Hanna; Steen Husted; Elaine M Hylek; Andrei D Mărgulescu; Lars Wallentin; Dan Atar Journal: Eur Heart J Date: 2015-09-14 Impact factor: 29.983
Authors: Gregory Y H Lip; Allison Keshishian; Shital Kamble; Xianying Pan; Jack Mardekian; Ruslan Horblyuk; Melissa Hamilton Journal: Thromb Haemost Date: 2016-08-19 Impact factor: 5.249
Authors: Peter A Noseworthy; Xiaoxi Yao; Neena S Abraham; Lindsey R Sangaralingham; Robert D McBane; Nilay D Shah Journal: Chest Date: 2016-09-28 Impact factor: 9.410
Authors: Bram J Geller; Robert P Giugliano; Eugene Braunwald; Sabina A Murphy; James J Hanyok; Jianqing Jin; Michele Mercuri; Elliott M Antman; Christian T Ruff Journal: Am Heart J Date: 2015-07-02 Impact factor: 4.749
Authors: Sana M Al-Khatib; Laine Thomas; Lars Wallentin; Renato D Lopes; Bernard Gersh; David Garcia; Justin Ezekowitz; Marco Alings; Hongqui Yang; John H Alexander; Gregory Flaker; Michael Hanna; Christopher B Granger Journal: Eur Heart J Date: 2013-04-17 Impact factor: 29.983
Authors: Sreekanth Vemulapalli; Anne S Hellkamp; W Schuyler Jones; Jonathan P Piccini; Kenneth W Mahaffey; Richard C Becker; Graeme J Hankey; Scott D Berkowitz; Christopher C Nessel; Günter Breithardt; Daniel E Singer; Keith A A Fox; Manesh R Patel Journal: Am Heart J Date: 2016-05-06 Impact factor: 4.749
Authors: Kenneth W Mahaffey; Susanna R Stevens; Harvey D White; Christopher C Nessel; Shaun G Goodman; Jonathan P Piccini; Manesh R Patel; Richard C Becker; Jonathan L Halperin; Werner Hacke; Daniel E Singer; Graeme J Hankey; Robert M Califf; Keith A A Fox; Günter Breithardt Journal: Eur Heart J Date: 2013-10-15 Impact factor: 29.983
Authors: M Cecilia Bahit; Renato D Lopes; Daniel M Wojdyla; Claes Held; Michael Hanna; Dragos Vinereanu; Elaine M Hylek; Freek Verheugt; Shinya Goto; John H Alexander; Lars Wallentin; Christopher B Granger Journal: Heart Date: 2016-10-24 Impact factor: 5.994
Authors: Madeleine Durand; Mireille E Schnitzer; Menglan Pang; Greg Carney; Sherif Eltonsy; Kristian B Filion; Anat Fisher; Min Jun; I Fan Kuo; Christel Renoux; J Michael Paterson; Jacqueline Quail; Alexis Matteau Journal: CMAJ Open Date: 2020-12-18
Authors: Wayne A Ray; Cecilia P Chung; C Michael Stein; Walter Smalley; Eli Zimmerman; William D Dupont; Adriana M Hung; James R Daugherty; Alyson Dickson; Katherine T Murray Journal: JAMA Date: 2021-12-21 Impact factor: 157.335
Authors: Ignacio Neumann; Holger J Schünemann; Lisa Bero; Graham Cooke; Nicola Magrini; Lorenzo Moja Journal: Bull World Health Organ Date: 2021-06-01 Impact factor: 9.408
Authors: Renate C A E van Uden; Marcel P H van den Broek; Ilse Houtenbos; Tessa C C Jaspers; Ankie M Harmsze; Hylke J Kingma; Diego A M Odekerken; Karina Meijer; Patricia M L A van den Bemt; Matthijs L Becker Journal: Eur J Clin Pharmacol Date: 2021-07-28 Impact factor: 2.953